{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T13:43:06Z","timestamp":1740145386096,"version":"3.37.3"},"reference-count":21,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,16]],"date-time":"2019-12-16T00:00:00Z","timestamp":1576454400000},"content-version":"vor","delay-in-days":1506,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"Sir Charles Gairdner Hospital"},{"DOI":"10.13039\/501100001801","name":"University of Western Australia","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001801","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","journals.elsevierhealth.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Molecular Diagnostics"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1016\/j.jmoldx.2015.05.009","type":"journal-article","created":{"date-parts":[[2015,8,28]],"date-time":"2015-08-28T20:51:23Z","timestamp":1440795083000},"page":"644-651","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Mutational Analysis of BRAF Inhibitor\u2013Associated Squamoproliferative Lesions"],"prefix":"10.1016","volume":"17","author":[{"given":"Britt","family":"Clynick","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tania","family":"Tabone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathryn","family":"Fuller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wendy","family":"Erber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katie","family":"Meehan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Millward","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin A.","family":"Wood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathan T.","family":"Harvey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jmoldx.2015.05.009_bib1","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmoldx.2015.05.009_bib2","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","article-title":"Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial","volume":"380","author":"Hauschild","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jmoldx.2015.05.009_bib3","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1111\/j.1365-2133.2012.11155.x","article-title":"Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma","volume":"167","author":"Anforth","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jmoldx.2015.05.009_bib4","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.jaad.2012.06.045","article-title":"Nonmalignant cutaneous findings associated with vemurafenib use in patients with metastatic melanoma","volume":"67","author":"Boyd","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jmoldx.2015.05.009_bib5","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.jaad.2012.04.008","article-title":"Diverse cutaneous side effects associated with BRAF inhibitor therapy: a clinicopathologic study","volume":"67","author":"Chu","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jmoldx.2015.05.009_bib6","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1097\/DAD.0b013e3182604873","article-title":"Squamoproliferative lesions arising in the setting of BRAF inhibitors","volume":"34","author":"Harvey","year":"2012","journal-title":"Am J Dermatopathol"},{"key":"10.1016\/j.jmoldx.2015.05.009_bib7","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/nature08833","article-title":"RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth","volume":"464","author":"Hatzivassiliou","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.jmoldx.2015.05.009_bib8","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.cell.2009.12.040","article-title":"Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF","volume":"140","author":"Heidorn","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.jmoldx.2015.05.009_bib9","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/nature08902","article-title":"RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF","volume":"464","author":"Poulikakos","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.jmoldx.2015.05.009_bib10","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1056\/NEJMoa1105358","article-title":"RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors","volume":"366","author":"Su","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmoldx.2015.05.009_bib11","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1158\/0008-5472.CAN-13-1065-T","article-title":"Vemurafenib cooperates with HPV to promote initiation of cutaneous tumors","volume":"74","author":"Holderfield","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.jmoldx.2015.05.009_bib12","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1111\/j.1755-148X.2012.01031.x","article-title":"Mutational analysis of cutaneous squamous cell carcinomas and verrucal keratosis in patients taking BRAF inhibitors","volume":"25","author":"Anforth","year":"2012","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.jmoldx.2015.05.009_bib13","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1200\/JCO.2011.36.7680","article-title":"RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors","volume":"30","author":"Oberholzer","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jmoldx.2015.05.009_bib14","doi-asserted-by":"crossref","unstructured":"Boussemart L, Girault I, Mateus C, Thomas M, Routier E, Cazenave H, Tomasic G, Wechlser J, Kamsu-Kom N, Roy S, Favre M, Lacroix L, Eggermont A, Vagner S, Robert C: BRAF inhibitors induce skin and extra-cutaneous tumors via paradoxical activation of the MAPK pathway: molecular study of 66 tumors and visualization of BRAF\/CRAF protein dimers [abstract 934]. Presented at the 105th Annual Meeting of the American Association for Cancer Research, 2014, April 5\u20139, San Diego, CA.","DOI":"10.1158\/1538-7445.AM2014-934"},{"key":"10.1016\/j.jmoldx.2015.05.009_bib15","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/CCO.0b013e3283436e8c","article-title":"RAF inhibition and induction of cutaneous squamous cell carcinoma","volume":"23","author":"Robert","year":"2011","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.jmoldx.2015.05.009_bib16","doi-asserted-by":"crossref","first-page":"901","DOI":"10.2217\/pgs.12.72","article-title":"Next-generation sequencing and large genome assemblies","volume":"13","author":"Henson","year":"2012","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.jmoldx.2015.05.009_bib17","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s13353-011-0057-x","article-title":"Sequencing technologies and genome sequencing","volume":"52","author":"Pareek","year":"2011","journal-title":"J Appl Genet"},{"key":"10.1016\/j.jmoldx.2015.05.009_bib18","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jmoldx.2013.05.003","article-title":"Clinical validation of a next-generation sequencing screen for mutational hotspots in 46 cancer-related genes","volume":"15","author":"Singh","year":"2013","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.jmoldx.2015.05.009_bib19","doi-asserted-by":"crossref","first-page":"6771","DOI":"10.1200\/JCO.2005.08.036","article-title":"Raf: a strategic target for therapeutic development against cancer","volume":"23","author":"Beeram","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jmoldx.2015.05.009_bib20","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/CCO.0b013e3282f5271c","article-title":"The MAPK pathway in melanoma","volume":"20","author":"Fecher","year":"2008","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.jmoldx.2015.05.009_bib21","doi-asserted-by":"crossref","first-page":"e00969","DOI":"10.7554\/eLife.00969","article-title":"BRAF inhibitors suppress apoptosis through off-target inhibition of JNK signaling","volume":"2","author":"Vin","year":"2013","journal-title":"Elife"}],"container-title":["The Journal of Molecular Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525157815001543?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525157815001543?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,12,15]],"date-time":"2019-12-15T22:45:25Z","timestamp":1576449925000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525157815001543"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["S1525157815001543"],"URL":"https:\/\/doi.org\/10.1016\/j.jmoldx.2015.05.009","relation":{},"ISSN":["1525-1578"],"issn-type":[{"type":"print","value":"1525-1578"}],"subject":[],"published":{"date-parts":[[2015,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mutational Analysis of BRAF Inhibitor\u2013Associated Squamoproliferative Lesions","name":"articletitle","label":"Article Title"},{"value":"The Journal of Molecular Diagnostics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jmoldx.2015.05.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 American Society for Investigative Pathology and the Association for Molecular Pathology. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}